Dare Bioscience, Inc. Increase Decrease In Operating Lease Liability
Dare Bioscience, Inc. (DARE) reported Increase Decrease In Operating Lease Liability of -$293.55 thousand for the 6-month period ending 2026-06-30, per its 10-Q filed 2026-08-13.
Financial Statements › Cash Flow › Operating Activities
us-gaap:IncreaseDecreaseInOperatingLeaseLiability · last filed 2026-08-13
- Dare Bioscience, Inc. increase decrease in operating lease liability for the quarter ending 2026-06-30 was -$148.44K.
- Dare Bioscience, Inc. increase decrease in operating lease liability for the quarter ending 2026-03-31 was -$145.11K.
- Dare Bioscience, Inc. increase decrease in operating lease liability for the quarter ending 2025-12-31 was -$143.41K.
- Dare Bioscience, Inc. increase decrease in operating lease liability for the quarter ending 2025-09-30 was -$138.89K.
- Dare Bioscience, Inc. increase decrease in operating lease liability for fiscal 2025 was -$548.64K.
- Dare Bioscience, Inc. increase decrease in operating lease liability for fiscal 2024 was -$459.76K, a 150.21% decline from fiscal 2023.
- Dare Bioscience, Inc. increase decrease in operating lease liability for fiscal 2023 was $915.73K.
| Period end | Increase Decrease In Operating Lease Liability 3 month | Increase Decrease In Operating Lease Liability 6 month | Increase Decrease In Operating Lease Liability 9 month | Increase Decrease In Operating Lease Liability 12 month |
|---|---|---|---|---|
| 2026-06-30 | -$148.44K derived: 10-Q 6 month − 10-Q 3 month · filed 2026-08-13 | -$293.55K 10-Q · filed 2026-08-13 | -$436.96K derived: sum of 3 quarters · filed 2026-08-13 | -$575.85K derived: sum of 4 quarters · filed 2026-08-13 |
| 2026-03-31 | -$145.11K 10-Q · filed 2026-05-14 | -$288.51K derived: sum of 2 quarters · filed 2026-05-14 | -$427.41K derived: sum of 3 quarters · filed 2026-05-14 | -$562.32K derived: sum of 4 quarters · filed 2026-08-13 |
| 2025-12-31 | -$143.41K derived: 10-K 12 month − 10-Q 9 month · filed 2026-03-26 | -$282.30K derived: sum of 2 quarters · filed 2026-03-26 | -$417.21K derived: sum of 3 quarters · filed 2026-08-13 | -$548.64K 10-K · filed 2026-03-26 |
| 2025-09-30 | -$138.89K derived: 10-Q 9 month − 10-Q 6 month · filed 2025-11-13 | -$273.80K derived: sum of 2 quarters · filed 2026-08-13 | -$405.23K 10-Q · filed 2025-11-13 | -$505.82K derived: sum of 4 quarters · filed 2026-08-13 |
| 2025-06-30 | -$134.91K derived: 10-Q 6 month − 10-Q 3 month · filed 2026-08-13 | -$266.34K 10-Q · filed 2026-08-13 | -$366.93K derived: sum of 3 quarters · filed 2026-08-13 | -$488.15K derived: sum of 4 quarters · filed 2026-08-13 |
| 2025-03-31 | -$131.43K 10-Q · filed 2026-05-14 | -$232.02K derived: sum of 2 quarters · filed 2026-05-14 | -$353.24K derived: sum of 3 quarters · filed 2026-05-14 | -$470.39K derived: sum of 4 quarters · filed 2026-05-14 |
| 2024-12-31 | -$100.59K derived: 10-K 12 month − 10-Q 9 month · filed 2026-03-26 | -$221.81K derived: sum of 2 quarters · filed 2026-03-26 | -$338.96K derived: sum of 3 quarters · filed 2026-03-26 | -$459.76K 10-K · filed 2026-03-26 |
| 2024-09-30 | -$121.22K derived: 10-Q 9 month − 10-Q 6 month · filed 2025-11-13 | -$238.37K derived: sum of 2 quarters · filed 2025-11-13 | -$359.17K 10-Q · filed 2025-11-13 | $850.71K derived: sum of 4 quarters · filed 2025-11-13 |
| 2024-06-30 | -$117.15K derived: 10-Q 6 month − 10-Q 3 month · filed 2025-08-14 | -$237.95K 10-Q · filed 2025-08-14 | $971.93K derived: sum of 3 quarters · filed 2025-08-14 | $871.37K derived: sum of 4 quarters · filed 2025-08-14 |
| 2024-03-31 | -$120.80K 10-Q · filed 2025-05-13 | $1.09M derived: sum of 2 quarters · filed 2025-05-13 | $988.52K derived: sum of 3 quarters · filed 2025-05-13 | $890.78K derived: sum of 4 quarters · filed 2025-05-13 |
| 2023-12-31 | $1.21M derived: 10-K 12 month − 10-Q 9 month · filed 2025-03-31 | $1.11M derived: sum of 2 quarters · filed 2025-03-31 | $1.01M derived: sum of 3 quarters · filed 2025-03-31 | $915.73K 10-K · filed 2025-03-31 |
| 2023-09-30 | -$100.56K derived: 10-Q 9 month − 10-Q 6 month · filed 2024-11-14 | -$198.31K derived: sum of 2 quarters · filed 2024-11-14 | -$294.15K 10-Q · filed 2024-11-14 | -$798.15K derived: sum of 4 quarters · filed 2024-11-14 |
| 2023-06-30 | -$97.74K derived: 10-Q 6 month − 10-Q 3 month · filed 2024-08-12 | -$193.59K 10-Q · filed 2024-08-12 | -$697.59K derived: sum of 3 quarters · filed 2024-08-12 | -$1.20M derived: sum of 4 quarters · filed 2024-08-12 |
| 2023-03-31 | -$95.85K 10-Q · filed 2024-05-14 | -$599.85K derived: sum of 2 quarters · filed 2024-05-14 | -$1.10M derived: sum of 3 quarters · filed 2024-05-14 | |
| 2022-12-31 | -$504.00K 10-K · filed 2023-03-30 | -$1.01M derived: sum of 2 quarters · filed 2023-03-30 | -$504.00K 10-Q · filed 2023-11-09 | |
| 2022-09-30 | -$504.00K 10-Q · filed 2022-11-10 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| KIORA PHARMACEUTICALS INC (KPRX) | United States | $0.012B | |
| Scienture Holdings, Inc. (SCNX) | United States | $0.012B | -0.38 |
| Phio Pharmaceuticals Corp. (PHIO) | United States | $0.012B | -0.92 |
| ADIAL PHARMACEUTICALS, INC. (ADIL) | United States | $0.012B | |
| Moleculin Biotech, Inc. (MBRX) | United States | $0.011B | |
| MetaVia Inc. (MTVA) | United States | $0.011B | -0.65 |
| KALA BIO, Inc. (KALA) | United States | $0.011B | -3.33 |
| BIOVIE INC. (BIVI) | United States | $0.012B | |
| Theriva Biologics, Inc. (TOVX) | United States | $0.011B | |
| Aspire Biopharma Holdings, Inc. (ASBP) | United States | $0.012B | -0.60 |